AUTH/3728/1/23: Complainant v Bristol Myers Squibb – alleged promotion of Zeposia (ozanimod hydrochloride) (No breach / not within scope)

📊

Key facts

⌄

Case number	AUTH/3728/1/23
Parties	Complainant v Bristol Myers Squibb
Product	Zeposia (ozanimod hydrochloride)
Allegation	Alleged promotion of Zeposia
Complaint received	11 January 2023
Case completed	20 February 2024
Outcome	No breach; not within the scope of the Code
Clauses cited	Not stated
Sanctions	Not stated
Case report	None (no breach / not within scope)
Source	https://www.pmcpa.org.uk/cases/completed-cases/auth3728123-complainant-v-bristol-myers-squibb

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

A complaint was made alleging promotion of Zeposia (ozanimod hydrochloride) by Bristol Myers Squibb.
Complaint received: 11 January 2023.
Case completed: 20 February 2024.

⚖️

⌄

No breach.
The matter was found to be not within the scope of the Code.
The PMCPA notes that, as this is no breach / not within scope, there is no case report.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

⭐ Charter Member — Until 31 March

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export. £1,999/year £2,499